AbbVie is giving up its patents on a combination drug that is being studied as a coronavirus treatment, becoming the first major drugmaker to drop its rights to make money from a drug that might be used during the pandemic.
艾伯維(AbbVie)將要放棄一種正被研究用於治療新型冠狀病毒的複合藥物的專利，成爲首家對一種本來有望在大流行病期間暢銷的藥物放棄權益的大型製藥商。
您已閱讀8%（297字），剩餘92%（3381字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。